Press Releases

Press Releases

  • September 10, 2020
    Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference
  • August 5, 2020
    Aileron Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
  • August 3, 2020
    Aileron Therapeutics to Present at Two Upcoming Investor Conferences in August
  • August 3, 2020
    Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924
  • June 29, 2020
    Aileron Therapeutics Initiates Enrollment in Schedule Optimization Part of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent in Small Cell Lung Cancer (SCLC) Patients Being Treated with Topotecan
  • June 10, 2020
    Aileron Therapeutics Announces Closing of Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares
  • June 4, 2020
    Aileron Therapeutics Announces Pricing of Public Offering of Common Stock
  • June 3, 2020
    Aileron Therapeutics Announces Proposed Public Offering of Common Stock
  • June 1, 2020
    Aileron Therapeutics Announces Positive Interim Results from Phase 1b/2 Clinical Trial of ALRN-6924 for the Prevention of Topotecan-induced Toxicities During Treatment for Small Cell Lung Cancer
  • May 27, 2020
    Aileron Therapeutics Announces Initiation of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent